Bone Biologics Corp (BBLG) USD0.001

Sell:$0.81Buy:$0.83$0.02 (1.95%)

Prices delayed by at least 15 minutes
Sell:$0.81
Buy:$0.83
Change:$0.02 (1.95%)
Prices delayed by at least 15 minutes
Sell:$0.81
Buy:$0.83
Change:$0.02 (1.95%)
Prices delayed by at least 15 minutes

Company Information

About this company

Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.

Key people

Jeffrey Frelick
President, Chief Executive Officer
Deina H. Walsh
Chief Financial Officer
Phillip T. Meikle
Director
Siddhesh Rajendra Angle
Independent Director
Robert E. Gagnon
Independent Director
Bruce Stroever
Independent Director
Click to see more

Key facts

  • EPIC
    BBLG
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US0980705018
  • Market cap
    $2.73m
  • Employees
    2
  • Shares in issue
    3.27m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.